BioSpace News Archive

MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, announced that study data shows THIO’s potent anticancer activity in Diffuse Intrinsic Pontine Glioma (DIPG), one of the most aggressive tumors affecting the central nervous system in children.

The Mark Foundation for Cancer Research announced an alliance with Takeda to accelerate the discovery and development of novel treatments for cancer.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the addition of two denosumab biosimilars referencing both Prolia ® and XGEVA ® to its biosimilar pipeline.

AGC Biologics today announced the completion of the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at the CDMO’s Heidelberg, Germany site.

Longhorn Vaccines and Diagnostics announced today new data from the USDA National Veterinary Services Laboratory validating the company’s core diagnostic product, PrimeStore® Molecular Transport Medium (PS-MTM), and its potential to inactivate highly consequential livestock and poultry viruses to support safer and more effective diagnostic testing.

Cryoport, Inc. announced that the Company has signed a new three-year supply chain solutions agreement with Monash IVF Group Limited, a leading provider of assisted reproductive services, as well as specialist women’s imaging and diagnostic services in Australia and Southeast Asia.

HCA Healthcare’s Johnston-Willis Hospital in Richmond, Virginia, is the first hospital in the United States to provide treatment in a new clinical trial for patients with brain metastases from lung cancer.

ReAlta Life Sciences was pleased to welcome Senator Mark R. Warner (D-Va) for an in-depth visit with the ReAlta management team, members of the ReAlta board of directors, and local investors on October 2, 2023.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma (HCC) with CARsgen’s innovative CAR-GPC3 T-cell therapy.

Alopexx, Inc. today announced that Daniel Vlock, MD, Co-Founder, Chief Executive Officer and Chairman of the Board of Alopexx, is scheduled to present at IDWeek’s 2023’s New Antimicrobials in the Pipeline symposium being held October 11-15, 2023 in Boston, MA.